A Phase 1 Study of AZD1775 (MK-1775) Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children With Diffuse Intrinsic Pontine Gliomas
This phase I trial studies the side effects and the best dose of WEE1 inhibitor MK-1775 when given together with local radiation therapy in treating patients with newly diagnosed diffuse intrinsic pontine gliomas.
The purpose of this study is to estimate the maximum tolerated dose (MTD) or recommended phase 2 dose and schedule of the Wee1 inhibitor AZD1775 (MK-1775) (WEE1 inhibitor MK-1775) administered concurrently with radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG); to define and describe the toxicities of AZD1775 (MK-1775) given concurrently with radiation therapy in children with newly diagnosed DIPG; and to characterize the pharmacokinetics of AZD1775 (MK-1775) in children with newly diagnosed DIPG.
- IRB Number: 1308763990 (PHO-COG-CROOP-ADVL1217)
- Research Study Identifier: TX6097
- Principal Investigator: James Croop, MD, PhD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required